4-chloro-6-(N,N-dimethylamino)-pyrido[3,4-d]pyrimidine | 189680-99-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 4-chloro-6-(N,N-dimethylamino)-pyrido[3,4-d]pyrimidine
• 英文别名: 4-chloro-N,N-dimethylpyrido[3,4-d]pyrimidin-6-amine
• CAS: 189680-99-7
• 化学式: C₉H₉ClN₄
• 分子量: 208.65
• InChiKey: QCEPAUUUYZXMGD-UHFFFAOYSA-N

物化性质

• 沸点：
  374.4±37.0 °C(Predicted)
• 密度：
  1.362±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  41.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-benzyloxy-3-chloroaniline 、 4-chloro-6-(N,N-dimethylamino)-pyrido[3,4-d]pyrimidine 生成 4-(4-Benzyloxy-3-chloroanilino)-6-(N,N-dimethylamino)pyrido[3,4-d]pyrimidine hydrochloride
  参考文献：
  名称：

  US6169091

  摘要：

  公开号：
• 作为产物：
  描述：

  6-氯吡啶并[3,4-d]嘧啶-4(3H)-酮 在 三乙胺 、 三氯氧磷 作用下， 以 乙醇 、 水 、 乙腈 为溶剂， 生成 4-chloro-6-(N,N-dimethylamino)-pyrido[3,4-d]pyrimidine
  参考文献：
  名称：

  Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2

  摘要：

  Described herein is the design and synthesis of indazolylaminopyridopyrimidines and quinazolines as inhibitors of the class 1 tyrosine kinase receptor family. Data is presented for N-4-(1-benzyl-1H-indazol-5-yl)-N-6,N-6-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine 3B. This compound inhibited EGFr and c-erbB-2 enzymes selectively over other kinases. It inhibited the proliferation of a range of tumour cell lines in vitro and the growth of BT474 xenografts in SCID mice. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00219-0

文献信息

• Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
  申请人：Glaxo Wellcome Inc.

  公开号：US06174889B1

  公开（公告）日：2001-01-16

  Substituted heteroaromatic compounds, and in particular substituted bicyclic heteroaromatic compounds of formula (I), wherein X is N or CH; A represents a fused 5, 6 or 7-membered heterocyclic ring containing 1 to 5 heteroatoms which may be the same or different and which are selected from N, O or S(O)m, wherein m is as defined above, the heterocyclic ring containing a total of 1, 2 or 3 double bonds inclusive of the bond in the pyridine or pyrimidine ring to which it is fused, with the provisos that the heterocyclic ring does not form part of a purine and that the fused heterocyclic ring does not contain two adjacent O or S(O)m atoms. U represents a 5 to 10-membered mono or bicyclic ring system in which one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from N, O and S(O)m, wherein m is 0, 1 or 2 and wherein the ring system is substituted by at least one independently selected R6 group and is optionally substituted by at least one independently selected R4 group, with the proviso that U does not represent phenyl; are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis.

  取代杂环芳香化合物，特别是式(I)的取代双环杂环芳香化合物，其中X为N或CH；A表示融合的含1至5个异原子的5、6或7元杂环，这些异原子可以相同或不同，并从N、O或S（O）m中选择，其中m如上所定义，杂环总共包含1、2或3个双键，包括与其融合的吡啶或嘧啶环中的键，但前提是杂环不是嘌呤的一部分，并且融合的杂环不包含两个相邻的O或S（O）m原子。U表示5至10个成员的单环或双环环系，其中一个或多个碳原子可以选择性地由N、O和S（O）m中独立选择的异原子替换，其中m为0、1或2，并且该环系被至少一个独立选择的R6基团取代，并且可以被至少一个独立选择的R4基团取代，但前提是U不代表苯基；这些化合物是蛋白酪氨酸激酶抑制剂。描述了这些化合物及其制备方法，包括这些化合物的制药组合物和它们在医药上的用途，例如用于癌症和牛皮癣的治疗。
• Protein tyrosine kinase inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US06723726B1

  公开（公告）日：2004-04-20

  Substituted heteroaromatic compounds, and in particular substituted bicyclic heteroaromatic compounds of formula (I), wherein X is N or CH; A represents a fused 5, 6 or 7-membered heterocyclic ring containing 1 to 5 heteroatoms which may be the same or different and which are selected from N, O or S(O)m, wherein m is as defined above, the heterocyclic ring containing a total of 1, 2 or 3 double bonds inclusive of the bond in the pyridine or pyrimidine ring to which it is fused, with the provisos that the heterocyclic ring does not form part of a purine and that the fused heterocyclic ring does not contain two adjacent O or S(O)m atoms. U represents a 5 to 10-membered mono or bicyclic ring system in which one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from N, O and S(O)m, wherein m is 0,1 or 2 and wherein the ring system is substituted by at least one independently selected R6 group and is optionally substituted by at least one independently selected R4 group, with the proviso that U does not represent phenyl; are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis.

  取代的杂环芳香化合物，特别是公式（I）中的取代双环杂环芳香化合物，其中X是N或CH；A代表融合的5、6或7个成员的杂环环，其中包含1到5个异原子，可以相同或不同，选择自N、O或S（O）m，其中m如上所定义，杂环环包含总共1、2或3个双键，包括与其融合的吡啶或嘧啶环中的键，但前提是杂环环不是嘌呤的一部分，并且融合的杂环环不包含两个相邻的O或S（O）m原子。U代表一个5到10个成员的单环或双环环系统，其中一个或多个碳原子可以被独立选择自N、O和S（O）m的杂原子替换，其中m为0、1或2，并且该环系统被至少一个独立选择的R6基团取代，并且可以被至少一个独立选择的R4基团取代，但前提是U不代表苯基；这些化合物是蛋白酪氨酸激酶抑制剂。描述了这些化合物的制备方法，包括这些化合物的制药组合物以及它们在医学上的使用，例如在癌症和牛皮癣的治疗中。
• US06169091A
  申请人：——

  公开号：——

  公开（公告）日：——
• BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP0912570B1

  公开（公告）日：2003-09-10
• US6174889B1
  申请人：——

  公开号：US6174889B1

  公开（公告）日：2001-01-16